Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Diroximel Fumarate in Healthy Chinese and Caucasian Adults
NCT05127564Phase 1Completed
- Sponsor
- Biogen
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of diroximel fumarate in multiple sclerosis (MS) (2 arms), sponsored by Biogen. Primary endpoints: Maximum Observed Concentration of MMF and Area Under the Concentration-Time Curve within a Dosing Interval of MMF. Started Dec 2021; status: completed.
02
Drugs
diroximel fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05127564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127564.